Elevated expression of Annexin II (Lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line
- 1 April 1992
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 65 (4), 498-502
- https://doi.org/10.1038/bjc.1992.103
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.1991
- Lipocortins: An updateProstaglandins, Leukotrienes & Essential Fatty Acids, 1991
- Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.Proceedings of the National Academy of Sciences, 1990
- Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell lineCancer Chemotherapy and Pharmacology, 1990
- Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma.Molecular and Cellular Biology, 1990
- EFFECT OF DURATION OF EXPOSURE TO VERAPAMIL ON VINCRISTINE ACTIVITY AGAINST MULTIDRUG-RESISTANT HUMAN-LEUKEMIC CELL-LINES1989
- THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCEAnnual Review of Biochemistry, 1989
- Tyrosine protein kinase substrate p36: A member of the annexin family of Ca2+/phospholipid‐binding proteinsCell Motility, 1989
- MULTIDRUG RESISTANCE IN A HUMAN SMALL-CELL LUNG-CANCER CELL-LINE SELECTED IN ADRIAMYCIN1987
- Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistanceNature, 1986